O Ðáó. åîïìïëïãåßôáé...

Boy ÇÔÁÍ ËÉÃÏ ÐÑÉÍ ÔÏ ÐÁÓ×Á ÖÅÔÏÓ ÏÔÁÍ ÅÂÃÁËÁ ÅÍÁ ÅËÊÏÓ ÓÔÁ ÃÅÍÍÇÔÉÊÁ ÌÏÕ ÏÑÃÁÍÁ.

ÅÍÔ¢ÎÅÉ ÁÖÏÕ ÔÏ ÁÖÇÓÁ ÃÉÁ ÁÑÊÅÔÏ ÊÁÉÑÏ ÊÁÍÏÍÔÁÓ ÔÁ ÄÉÊÁ ÌÏÕ ÃÉÁÔÑÏÓÏÖÉÁ, ÊÑÅÌÅÓ Ê.Ô.Ë. ÁÐÏÖÁÓÉÓÁ ÍÁ ÐÁÙ ÓÅ ÅÍÁ ÍÏÓÏÊÏÌÅÉÏ ÃÉÁ ÍÁ ÄÙ ÔÉ ÅÉÍÁÉ.

ÄÅÍ ÖÁÍÔÁÆÏÌÏÕÍ ÌÅ ÔÉÐÏÔÁ ÏÔÉ ÌÐÏÑÅÉ ÍÁ ÅÉÍÁÉ ÁÕÔÏ.
ÅÉÌÁÉ ÐÁÍÔÑÅÌÅÍÏÓ ÅÄÙ ÊÁÉ 4 ×ÑÏÍÉÁ ÊÁÉ Å×Ù ÌÉÁ ÕÃÉÅÓÔÁÔÇ ÊÏÑÏÕËÁ 2 ÅÔÙÍ.

ÓÔÉÓ ÅÎÅÔÁÓÅÉÓ ÐÏÕ ÅÊÁÍÅ Ç ÃÕÍÁÉÊÁ ÌÏÕ ÓÔÇÍ ÅÃÊÕÌÏÓÕÍÇ ÄÅÍ ÅÄÅÉ×ÍÅ ÔÉÐÏÔÁ, ÃÉÁÔÉ ÅÊÁÍÅ TEST ÊÁÉ ÃÉÁ HIV.

Ï ÃÉÁÔÑÏÓ ÌÏÕ ÅÉÐÅ ÐÙÓ ÌÁËËÏÍ ÅÉÍÁÉ ÅÑÐÇÓ, ÁËËÁ ÍÁ ÊÁÍÙ ÊÁÉ ÊÁÐÏÉÅÓ ÁËËÅÓ ÅÎÅÔÁÓÅÉÓ ÌÅÓÁ ÓÔÉÓ ÏÐÏÉÅÓ ÇÔÁÍ ÊÁÉ ÃÉÁ ÔÏÍ HIV.
ÔÅËÉÊÁ ÔÉÓ ÅÊÁÍÁ.
ÊÁÉ ÏÔÁÍ ÐÇÃÁ ÓÔÏ ÅÑÃÁÓÔÇÑÉÏ, ÁÊÏÕÓÁ ÐÙÓ ÅÉÌÁÉ ÈÅÔÉÊÏÓ ÊÁÉ ÌÁËÉÓÔÁ ÔÏ ÉÉÊÏ ÖÏÑÔÉÏ ÌÏÕ ÇÔÁÍ 50 ÖÏÑÅÓ ÐÁÍÙ ÁÐÏ ÔÏ ÖÕÓÉÏËÏÃÉÊÏ.

ÔÑÅËÁÈÇÊÁ ÊÁÉ Ç ÌÏÍÇ ÌÏÕ ÓÊÅØÇ ÃÉÁ ÌÅÑÅÓ HÔAN Ç ÁÕÔÏÊÔÏÍÉÁ ÁËËÁ ÓÊÅÖÔÏÌÏÕÍ ÐÙÓ ÔÏ ÁÃÃÅËÏÕÄÉ ÌÏÕ ÌÅ ÅÉ×Å ÁÍÁÃÊÇ ÅÓÔÙ ÊÁÉ ÌÉÁ ÙÑÁ ÆÙÇÓ ÁÊÏÌÁ ÍÁ ÌÏÕ ÅÌÅÍÅ.
ÐÇÃÁ ÓÔÏÍ ÃÉÁÔÑÏ ÌÅ ÔÉÓ ÅÎÅÔÁÓÅÉÓ ÊÁÉ ÁÑ×ÉÓÅ ÍÁ ÌÅ ÑÙÔÁÅÉ ÄÉÁÖÏÑÁ ÏÐÙÓ ÓÅÎÏÕÁËÉÊÇ ÆÙÇ ÊÔË.
ÔÏÕ ÅÉÐÁ ÏÔÉ ÅÉÌÁÉ STRAIGHT, ÐÁÍÔÑÅÌÅÍÏÓ, ÌÅ ÐÁÉÄÉ ÊÁÉ ÅÑÙÔÉÊÇ ÆÙÇ ÐÏËÕ ÖÕÓÉÏËÏÃÉÊÇ. ÍÁÑÊÙÔÉÊÁ ÐÏÔÅ.
ÁÕÔÅÓ ÇÔÁÍ ÏÉ ÁÐÁÍÔÇÓÅÉÓ ÐÏÕ ÐÇÑÅ ÊÁÉ ÏÌÙÓ ÊÏËËÇÓÁ HIV!

ÊÁÍÁÌÅ ÅÎÅÔÁÓÅÉÓ ÃÉÁ ÍÁ ÄÏÕÌÅ ÔÁ CD4 ÊÁÉ Ç ÁÐÁÍÔÇÓÇ ÁÑÃÇÓÅ ÌÏÍÏ ÄÕÏ ÌÅÑÅÓ.
ÔÁ CD4 ʾÔÔÁÑÁ ÇÔÁÍ 120 ÊÁÉ ÔÏ ÉÉÊÏ ÖÏÑÔÉÏ ÇÔÁÍ 20000.
ÏÕÔÅ Ï ÃÉÁÔÑÏÓ ÄÅÍ ÔÏ ÐÉÓÔÅÕÅ, ÁËËÁ ÊÁÐÏÉÁ ÁÐÏ ÔÁ ÓÕÌÐÔÙÌÁÔÁ ÐÏÕ ÔÏÕ ÅÄÅÉÎÁ ÔÏÍ ÅÐÅÉÓÁÍ ÏÔÉ ÏÉ ÅÎÅÔÁÓÅÉÓ ÅÉÍÁÉ ÓÙÓÔÅÓ.

ÁÑ×ÉÓÁ ÁÌÅÓÙÓ ÔÁ ÖÁÑÌÁÊÁ ÊÁÉ ÏËÁ ÐÁÍÅ ÊÁËÁ.
ÔÁ CD4 ÐÇÃÁÍ 280 ÊÁÉ Ï ÃÉÁÔÑÏÓ ËÅÅÉ ÏÔÉ ÏËÁ ÐÁÍÅ ÊÁÔÅÕ×ÇÍ.

ÓÁÓ ÔÁ ÅÃÑÁØÁ ÏËÁ ÁÕÔÁ Ï×É ÃÉÁ ÍÁ ÓÁÓ ÊÏÕÑÁÓÙ, ÁËËÁ ÃÉÁ ÍÁ ÊÁÔÁËÁÂÏÕÍ ÔÁ ÍÅÁ ÐÁÉÄÉÁ ÊÕÑÉÙÓ ÐÏÕ ÌÐÁÉÍÏÕÍ ÅÄÙ ÌÏËÉÓ ÌÁÈÁÉÍÏÕÍ ÏÔÉ ÅÉÍÁÉ ÈÅÔÉÊÏÉ, ÃÉÁÔÉ ÅÔÓÉ ÅÊÁÍÁ ÊÉ ÅÃÙ ÊÁÉ ÁÐÏ ÅÄÙ ÅÐÁÉÑÍÁ ÊÏÕÑ¢ÃÉÏ, ÃÉÁÔÉ ÇÎÅÑÁ ÐÏËÕ ËÉÃÁ ÃÉÁ ÔÏÍ HIV, ÍÁ ÌÇÍ ÖÏÂÏÕÍÔÁÉ ÊÁÉ ÍÁ EXOÕÍ ÄÕÍÁÌÇ ÃÉÁÔÉ ÌÐÏÑÏÕÌÅ ÍÁ ÆÇÓÏÕÌÅ ÌÅ ÔÏÍ HIV ÖÕÓÉÏËÏÃÉÊÁ.

ÄÕÓÔÕ×¿Ó Ç ÃÕÍÁÉÊÁ ÌÏÕ ÊÏËËÇÓÅ ÁÐÏ ÌÅÍÁ ÁËËÁ ÔÏ ÐÁÉÄÉ ÄÏÎÁ ÔÏÍ ÈÅÏ ÁÐÏ ÈÁÕÌÁ Ï×É.




... 'Aëëåò éóôïñßåò ...

+/-
ÌÜèå ôï status óïõ

Âñåò ôï ãéáôñü óïõ

ÐÜñå èåñáðåßá

¸ëåãîå ôï ééêü óïõ öïñôßï

Lancet

Ðñüóöáôåò äçìïóéåýóåéò óôï ðåñéïäéêü The Lancet HIV

Optimised second-line regimens in the public health approach

Globally, most people receive antiretroviral therapy (ART) in programmes that follow the WHO-recommended public health approach, using a small number of standard regimens and simplified monitoring.1 A single standard regimen—dolutegravir (an integrase strand transfer inhibitor [INSTI]) with tenofovir disoproxil fumarate and lamivudine (both nucleoside reverse transcriptase inhibitors, [NRTIs])—is currently taken by the large majority of people on ART in these programmes, including those on second-line therapy (following previous failure of a non-NRTI regimen).

Prioritising HIV drug resistance testing according to risk

Tenofovir–lamivudine–dolutegravir (TLD) is recommended as an initial treatment regimen and a preferred optimised regimen for people living with HIV without a history of previous viral non-suppression, referred to as TLD in first-line therapy (TLD-1). For people living with HIV with persistent viral non-suppression, TLD largely replaced protease inhibitor-based regimens following efavirenz-based initial regimens, referred to as TLD in second-line therapy (TLD-2), as it is at least as effective, better tolerated, and more affordable.

Ending paediatric AIDS: time to close implementation gaps

WHO's global health sector strategies on HIV, conceived to guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS by 2030, target a reduction in the number of children aged 0–14 years newly infected with HIV from 150 000 in 2022 to 20 000 in 2025 and 15 000 in 2030.1 To track progress toward these targets, accurate estimations of the number of annual infections in children in each country is crucial. However, in many low-income and middle-income countries, where the burden of paediatric HIV is the highest, children are not systematically tested for HIV in programmes for the prevention of vertical transmission (PVT).

About us

Óôï hivaids.gr, öéëïîåíïýìå áöéëïêåñäþò ôï "Ðñüãñáììá Óõíåñãáóßáò" ÌïíÜäùí Ëïéìþîåùí ãéá ôçí áíÜðôõîç äéáäéêôõáêÞò ôñÜðåæáò êëéíéêþí ðáñáìÝôñùí. Ôï Ðñüãñáììá äçìéïõñãÞèçêå áðü Ýíáí ãéáôñü åéäéêü óôçí HIV ëïßìùîç ìå ôç óõììåôï÷Þ ôùí ÌïíÜäùí: Ðåñéóóüôåñá

% Áíáðçñßá êáé HIV

ÍÝïò êáíïíéóìüò

Åíéáßïò Ðßíáêáò Ðñïóäéïñéóìïý Ðïóïóôïý Áíáðçñßáò

Çìåñïëüãéï

@ Äéáýãåéá

ÄéáýãåéáÄé@ýãåéá

äéáöÜíåéá óôï êñÜôïò

ÄéáäéêôõáêÝò áíáñôÞóåéò äéïéêçôéêþí áðïöÜóåùí ãéá ôï HIV/AIDS

Twitter

¸ñåõíá

Óáò Ý÷åé óðÜóåé ðïôÝ ôï ðñïöõëáêôéêü êáôÜ ôç äéÜñêåéá ìéáò åñùôéêÞò åðáöÞò;
Íáé
¼÷é
Äåí ÷ñçóéìïðïéþ

Åðéêïéíùíßá

Newsletter

Áíáêïéíþóåéò

×ñÞóéìåò ðëçñïöïñßåò